Figure 1.  SCI presented work on cancer immunotherapy research.

The field of cancer immunotherapy has grown rapidly since the discovery of immune checkpoint molecules by James Allison, back in 2 decades ago. Following the success of Ipilimumab (Yervoy) - an immune checkpoint inhibitor, there were several novel technologies had been approved as treatment modalities for certain cancer indications. CAR-T cells, bi-specific antibodies and oncolytic virus platforms along with the wave of programmed cell death protein-1 (PD1) and PD1 ligand (PDL1) blocking antibodies were names of modalities which had also been  approved between 2011 - 2016.

These progress in the field of cancer immunotherapy were covered in the ASCO-SITC Clinical Immuno-Oncology Symposium event, which held on 25-27 January 2018 in San Francisco, California. The event had gathered not less than 1000 scientist, oncologist, and global participants to discuss and explore area related to recent advances in clinical and translational research and breakthroughs in cancer immunotherapy and its implications for clinical care. There were topics that could be highlighted as they illustrated the future trend in this field, such as the combination of immune checkpoint inhibitor with other modalities that have already been applied in several clinical trial, exploration on specific biomarkers to stratify patients and advances in CAR T-cell for hematologic malignancies.

In this very influential event, SCI shared their work on cancer immunotherapy research through poster presentation entitled "Profile of Programmed Death Ligand 1 Expression and PD-L1 Gene Amplification in Indonesian Colorectal Cancer Patients", presented by Akterono Dwi Budiyati, M. Biomed. The work was a collaborative research between SCI and Medistra Hospital (Prof. dr. Antonius Nikolas Kurniawan, Sp.PA (K), Prof. Dr. dr. Aru Wisaksono Sudoyo, Sp.PD-KHOM, FACP and dr. Fritzie Rexana). This participation hopefully can further improve the contribution of SCI as research institution together with its collaborators, in this rapidly growing field.

Post Rating


There are currently no comments, be the first to post one.

Post Comment

Only registered users may post comments.

News & Events



SCI - Events

Stem Cell News

Cell Therapy News

Cancer News

Internship Program